Rgenta Therapeutics, Inc.
StreetZero Signal 71
About Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. is a privately held biotechnology company developing oral small-molecule RNA-targeting medicines. Its proprietary platform mines genomics data to identify targetable RNA processing events and designs small-molecule glues to modulate spliceosome, regulatory proteins, and RNAs. The company focuses initially on oncology and neurological disorders, with lead program RGT-61159 in Phase 1 trials for adenoid cystic carcinoma and colorectal cancer. It maintains headquarters in Woburn, Massachusetts.
LATEST FUNDINGPrivate Placement
$41.9M
Announced 2026-11-03
IN THE NEWS
- 🔗 Rgenta - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Rgenta Therapeutics, Inc.
- 🔗 Rgenta Therapeutics Raises $52M in Series A Financing | Delos Capital
- 🔗 Rgenta Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 GSK arms Rgenta with up to $500M per RNA target
EMPLOYEES—
FOUNDED2020
HQWoburn, Massachusetts, United States
Industry
Other Technology
Tags
BiotechRNA TherapeuticsOncologyPlatform
Investors
Key highlights
- Raised $52M Series A in 2022 to advance RNA splice-modulator pipeline.
- Lead asset RGT-61159 in Phase 1 for adenoid cystic carcinoma and colorectal cancer.
- Entered collaboration with GSK for up to $500M per RNA target.
- Platform identifies RNA processing events and designs small-molecule glues.
- 13 institutional investors including Matrix Partners China and AstraZeneca.
Ask StreetZero about Rgenta Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account